Issue 12, 2019

A bioactivatable self-quenched nanogel for targeted photodynamic therapy

Abstract

Photodynamic therapy has attracted significant attention due to its localized treatment advantage. However, the non-specific distribution of photosensitizers and the subsequent potential toxicity caused by sunshine exposure hinder its wide adoption in cancer treatment. To minimize these unwanted effects and improve its efficacy, we developed a bioactivatable self-quenched nanogel, which remains in its inactive state in healthy tissues. Anti-EGFR Affibody decorated nanogels can effectively target head and neck cancer and release activated pheophorbide A in a reducing environment, such as in the tumor stroma and cytoplasm. Consequently, the EGFR targeted nanogel coupled with NIR irradiation alleviates tumor burden by 94.5% while not inducing systemic toxicity.

Graphical abstract: A bioactivatable self-quenched nanogel for targeted photodynamic therapy

Supplementary files

Article information

Article type
Paper
Submitted
05 Aug 2019
Accepted
18 Sep 2019
First published
19 Sep 2019

Biomater. Sci., 2019,7, 5143-5149

A bioactivatable self-quenched nanogel for targeted photodynamic therapy

H. He, A. Nieminen and P. Xu, Biomater. Sci., 2019, 7, 5143 DOI: 10.1039/C9BM01237K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements